Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer

International Journal of Cancer

Volumn 136, Issue 8, 2015, Pages 1863-1873

  Alonso Alconada, Lorena ^a   Santacana, Maria ^b   Garcia Sanz, Pablo ^c   Muinelo Romay, Laura ^a   Colas, Eva ^d   Mirantes, Cristina ^b   Monge, Marta ^d   Cueva, Juan ^a   Oliva, Esther ^e   Soslow, Robert A ^f   Lopez, Maria Angeles ^g   Palacios, Jose ^g   Prat, Jaime ^h   Valls, Joan ^b   Krakstad, Camilla ^i,j   Salvesen, Helga ^i,j   Gil Moreno, Antonio ^d   Lopez Lopez, Rafael ^a   Dolcet, Xavier ^b   Moreno Bueno, Gema ^c,k   Reventos, Jaume ^d,l,m   Matias Guiu, Xavier ^a,b   Abal, Miguel ^a   more..

^a Instituto de Investigación Sanitaria de Santiago de Compostela IDIS   (Spain)

^b UNIVERSITY OF LLEIDA   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY OF BERGEN   (Norway)

^k UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^l UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^m BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

more..

Author keywords

ANXA2; Biomarker; Endometrial cancer; Metastasis; Recurrent disease

Indexed keywords

LIPOCORTIN 2; TUMOR MARKER; ANXA2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CIRCULATING TUMOR CELL; CLONOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; ENDOMETRIUM CANCER; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PREDICTIVE VALUE; PRIMARY TUMOR; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY ANALYSIS; VALIDATION STUDY; AGED; ANIMAL; BLOOD; ENDOMETRIAL NEOPLASMS; METABOLISM; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NUDE MOUSE; PROCEDURES; TUMOR EMBOLISM;

AGED; ANIMALS; ANNEXIN A2; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; PROTEOMICS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84922537745     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29213     Document Type: Article

References (35)

1. Wright JD, Barrena Medel NI, Sehouli J, et al. Contemporary management of endometrial cancer. Lancet 2012;379:1352-60.
2. Benedetti Panici P, Basile S, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707-16.
3. Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125-36.
4. Faca VM, Ventura AP, Fitzgibbon MP, et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One 2008;3:e2425.
5. Salamonsen LA, Edgell T, Rombauts LJ, et al. Proteomics of the human endometrium and uterine fluid: a pathway to biomarker discovery. Fertil Steril 2013;99:1086-92.
6. Casado-Vela J, Rodriguez-Suarez E, Iloro I, et al. Comprehensive proteomic analysis of human endometrial fluid aspirate. J Proteome Res 2009;8:4622-32.
7. DeSouza LV, Taylor AM, Li W, et al. Multiple reaction monitoring of mTRAQ-labeled peptides enables absolute quantification of endogenous levels of a potential cancer marker in cancerous and normal endometrial tissues. J Proteome Res 2008;7:3525-34.
8. Farias-Eisner G, Su F, Robbins T, et al. Validation of serum biomarkers for detection of earlyand late-stage endometrial cancer. Am J Obstet Gynecol 2010;202:73 e1-5.
9. Brennan DJ, Hackethal A, Metcalf AM, et al. Serum HE4 as a prognostic marker in endometrial cancer - a population based study. Gynecol Oncol 2014;132:159-65.
10. Zeimet AG, Reimer D, Huszar M, et al. LICAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 2013;105:1142-50.
11. Meehan KL, Rainczuk A, Salamonsen LA, et al. Proteomics and the search for biomarkers of female reproductive diseases. Reproduction 2010;140:505-19.
12. Van Gorp T, Cadron I, Vergote I. The utility of proteomics in gynecologic cancers. Curr Opin Obstet Gynecol 2011;23:3-7.
13. Monge M, Doll A, Colas E, et al. Subtractive proteomic approach to the endometrial carcinoma invasion front. J Proteome Res 2009;8:4676-84.
14. Sorolla A, Yeramian A, Valls J, et al. Blockade of NFkappaB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. Mol Oncol 2012;6:530-41.
15. Alonso-Alconada L, Muinelo-Romay L, Madissoo K, et al. Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer, in press.
16. Gemoll T, Habermann JK, Lahmann J, et al. Protein profiling of genomic instability in endometrial cancer. Cell Mol Life Sci 2012;69:325-33.
17. Habermann JK, Bundgen NK, Gemoll T, et al. Genomic instability influences the transcriptome and proteome in endometrial cancer subtypes. Mol Cancer 2011;10:132.
18. Kuhajda FP, Piantadosi S, Pasternack GR. Haptoglobinrelated protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 1989;321:636-41.
19. Gast MC, van Tinteren H, Bontenbal M, et al. Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. BMC Cancer 2008;8:389.
20. Paternoster D, Cartei G, Campagnutta E, et al. Acute reactive stage proteins in gynaecologic cancers. Eur J Gynaecol Oncol 1980;1:94-8.
21. Suh DH, Kim HS, Chung HH, et al. Pre-operative systemic inflammatory response markers in predicting lymph node metastasis in endometrioid endometrial adenocarcinoma. Eur J Obstet Gynecol Reprod Biol 2012;162:206-10.
22. Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol 2008;216:131-40.
23. Zhang X, Liu S, Guo C, et al. The association of annexin A2 and cancers. Clin Transl Oncol 2012;14:634-40.
24. Maxwell GL, Hood BL, Day R, et al. Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation. Gynecol Oncol 2011;121:586-94.
25. Zhou S, Yi T, Liu R, et al. Proteomics identification of annexin A2 as a key mediator in the metastasis and proangiogenesis of endometrial cells in human adenomyosis. Mol Cell Proteomics 2012;11:M112 017988.
26. Garrido-Gomez T, Dominguez F, Quinonero A, et al. Annexin A2 is critical for embryo adhesiveness to the human endometrium by RhoA activation through F-actin regulation. FASEB J 2012;26:3715-27.
27. Valapala M, Vishwanatha JK. Lipid raft endocytosis and exosomal transport facilitate extracellular trafficking of annexin A2. J Biol Chem 2011;286:30911-25.
28. Vedeler A, Hollas H, Grindheim AK, et al. Multiple roles of annexin A2 in post-transcriptional regulation of gene expression. Curr Protein Pept Sci 2012;13:401-12.
29. Colas E, Pedrola N, Devis L, et al. The EMT signaling pathways in endometrial carcinoma. Clin Transl Oncol 2012;14:715-20.
30. Nieto MA, Cano A. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol 2012;22:361-8.
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
32. Oppenheimer SB. Cellular basis of cancer metastasis: a review of fundamentals and new advances. Acta Histochem 2006;108:327-34.
33. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-21.
34. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
35. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castrationresistant prostate cancer. Clin Cancer Res 2008;14:6302-9.